

PHILADELPHIA, Dec. 6 (UPI) -- Three U.S. health institutions say they've joined to evaluate a potential vaccine designed to prevent transmission of malaria from mosquitoes to humans.
The PATH Malaria Vaccine Initiative, the National Institute of Allergy and Infectious Diseases and the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research will collaborate to conduct a Phase 1 clinical trial in healthy adults to assess the safety and effectiveness of the vaccine, a PATH release said Tuesday.
The Pfs25 vaccine aims to block transmission of malaria from mosquitoes to humans by preventing the malaria parasite from developing in the mosquito, researchers said.
"This is the first clinical trial supported by MVI to use a transmission-blocking approach," Ashley Birkett, director of research and development at MVI, said. "Eradication of malaria may be decades away, but we believe a successful TBV [transmission-blocking vaccine] -- used alongside safe and effective drugs, insecticides, bed nets and possibly a malaria vaccine that protects the individual against infection and disease -- would be essential to achieving that goal."
|
|
|
|
|
|
| Additional Health News Stories | |
NEWARK, N.J., May 18 (UPI) --
A US Airways plane with 31 passengers aboard crash-landed at the Newark, N.J., airport early Saturday after its landing gear failed to deploy, officials said.
|
LOS ANGELES, May 18 (UPI) --
A lawyer representing the estate of Michael Jackson's manager has emails the pop star's lawyers said could be key in the wrongful death trial against AEG Live.
|
HADEERA, Israel, May 18 (UPI) --
A hiker was hospitalized after a sheep attacked him Saturday on the Israel National Trail, authorities said.
|
NEW YORK, May 18 (UPI) --
Wall Street data distributor Bloomberg LP said it was taking steps to get ahead of damage that may erupt from revelations of a privacy breach at the company.
|
| Stories | Photos | Comments |
View Caption